Re: Oversight of Clinical Investigators

FDA Adverse Event Information, Medical Device Approval Process, and FDA Corruption

Re: Oversight of Clinical Investigators

PostPosted by hopeful19 » Thu Mar 24, 2011 12:37 am

http://www.gao.gov/products/GAO-09-807

Oversight of Clinical Investigators: Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators
GAO-09-807 September 25, 2009


Summary
The Food and Drug Administration (FDA) oversees the clinical investigators who conduct research involving new drugs, biologics, and medical devices to ensure that their conduct does not compromise the safety of clinical trial participants or the integrity of clinical trial data. FDA can debar or disqualify investigators who have engaged in misconduct such as submitting fraudulent data. Debarred or disqualified investigators cannot engage in certain activities related to clinical research. GAO was asked to review FDA's debarment and disqualification processes. GAO examined the length of time debarment and disqualification processes have taken and factors for those time frames, and the statutory and regulatory limitations of debarment and disqualification. GAO reviewed laws, regulations, and FDA files through November 5, 2008, for (1) all investigators, study coordinators, and sub-investigators for whom FDA pursued debarment since receiving debarment authority in 1992; and (2) all clinical investigators for whom FDA pursued disqualification since FDA adopted its current process for initiating proceedings in 1998.

More than half of the debarment proceedings in GAO's review took 4 or more years, and factors contributing to these time frames included internal control weaknesses in the debarment process and competing priorities among responsible staff. FDA has statutory authority to debar individuals who have been convicted of felonies or certain misdemeanors related to the development, approval, or regulation of a drug or biologic. For the 18 proceedings GAO reviewed, the length of time from an individual's conviction through debarment (or as of November 5, 2008, for pending proceedings) ranged from about 1 year to nearly 11 years. Factors that contributed to delays included that FDA staff faced competing priorities and FDA had not established internal controls, such as time frames for the completion of steps in the debarment process. FDA has made or planned changes that could improve timeliness (e.g., by establishing time frames in March 2009), but the effects of such actions have yet to be seen. The time taken for disqualification proceedings varied and proceedings took longer when the investigator contested disqualification. FDA may disqualify investigators who repeatedly or deliberately failed to comply with FDA regulations or submitted false information to FDA or the sponsor of a clinical trial. For the 52 disqualification proceedings GAO reviewed, the length of time from initiation of a disqualification proceeding to its conclusion (or as of November 5, 2008, for pending proceedings) ranged from 26 days to more than a decade, with about one-third taking more than 2 years. In general, the more steps taken by the investigator to contest disqualification, the longer it took to complete the proceeding. Disqualification proceedings initiated in 1998 through 2001 generally took longer than proceedings that were initiated more recently. FDA officials told us that a lack of time frames for these proceedings--an internal control weakness--may have contributed to longer proceedings. FDA made changes to its disqualification process (e.g., by establishing time frames in June 2008 and January 2009) that could further improve timeliness, but the full effect of these changes remains to be seen. FDA's debarment authority does not fully extend to involvement with medical devices, and its regulations do not extend disqualification for drugs and biologics to medical devices and vice versa. As a result, an individual may be debarred from involvement with drugs and biologics, but not from involvement with medical devices, regardless of the kind of misconduct in which the individual engaged. FDA's disqualification regulations allow an investigator who is disqualified for conduct related to drugs or biologics to serve as an investigator for medical devices; likewise, an individual who FDA disqualified for conduct related to medical devices remains able to serve as a clinical investigator for drugs and biologics.



Recommendations
Our recommendations from this work are listed below with a Contact for more information. Status will change from "In process" to "Open," "Closed - implemented," or "Closed - not implemented" based on our follow up work.

Director: Marcia G. Crosse
Team: Government Accountability Office: Health Care
Phone: (202) 512-3407


Recommendations for Executive Action

Recommendation: The Commissioner of FDA should take the necessary steps to pursue debarment authority for medical devices that is consistent with the current debarment authority for drugs and biologics and prohibit any debarred individual from involvement with drugs, biologics, and medical devices.

Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration

Status: Open

Comments: In its written comments on a draft of our report, FDA indicated that having debarment authority to prohibit individuals and companies convicted of certain crimes, or otherwise involved in criminal activity, from involvement in the medical device industry would benefit the development and approval process for medical devices. FDA recently confirmed its support for extending its debarment authority to include persons involved in the medical device industry. A bill that would grant FDA this authority--H.R.3932-- has been introduced and referred to the House Committee on Energy and Commerce. In the 2010 update from FDA, they reiterated their support for the expansion of its statutory debarment authority.

Recommendation: The Commissioner of FDA should take the necessary steps to amend FDA regulations to ensure that those who have engaged in misconduct found sufficiently serious to warrant disqualification for one investigational medical product are not able to continue to serve as clinical investigators for any.

Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration

Status: Open

Comments: In its written comments on a draft of our report, FDA indicated that it intends to pursue revision of its regulations concerning clinical investigator disqualification to implement our recommendation. FDA reported that it intends to issue a proposed rule to expand the scope of disqualification of clinical investigators to include all types of FDA regulated investigational products by the end of 2010.

Recommendation: The Commissioner of FDA should take the necessary steps to monitor compliance with recently established time frames for debarment and disqualification proceedings and take appropriate action when those are not met.

Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration

Status: Open

Comments: In its written comments on a draft of our report, FDA summarized several steps it is taking to ensure timely actions in debarment and disqualification proceedings. In its 2010 update, FDA indicated that since 2008, FDA has initiated 16 disqualification actions. Of these, 11 actions are final and 5 pending. Final actions were completed in less than one year. In addition, for disqualification, among these efforts are two recently issued guidance documents to IRBs, clinical investigators, and sponsors. The first guidance document explains FDA's disqualification process, the consequences of disqualification for the clinical investigator, and the impact on any ongoing and completed clinical trials. The second guidance, explains FDA's process for conducting inspections of clinical investigators, including the identification of commonly observed deficiencies and FDA's post-inspection correspondence and actions.
"There's almost no risk involved," says Stephen Fanning, CEO of Solta Medical, which owns Fraxel.

The world is a dangerous place to live, not because of the people who do evil, but rather those who sit back & let it happen.
-Einstein
hopeful19
Long Time Member
Long Time Member
 
Posts: 1580
Joined: Fri Jun 18, 2010 5:47 pm

Return to FDA

Who is online

Users browsing this forum: No registered users and 0 guests

cron